Search Results
Oct 02, 2025, 18:37 ET FDA Approves Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
discontinue ZEPZELCA based on severity. In the IMforte study, based on laboratory values, increased alanine aminotransferase (ALT) occurred in 25%, including 3% Grade 3 or Grade 4 in patients who received ZEPZELCA in combination with atezolizumab. Increased aspartate aminotransferase
More news about: Jazz Pharmaceuticals plc
Oct 02, 2025, 16:00 ET ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Oct. 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
Hepatotoxicity . Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory
More news about: Celltrion
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
erythrodysesthesia (11%), nausea (9%), stomatitis (9%), musculoskeletal pain (8%), rash (8%), increased lipase (7%), abdominal pain (6%), vomiting (6%), increased ALT (5%), and increased amylase (5%). In RCC, the most common adverse reactions (≥30%) observed in LENVIMA + everolimus–treated patients
More news about: Eisai Inc.
Oct 02, 2025, 08:00 ET SEI Announces Strategic Partnership with Graphene
investment in Ctrl Alt, a leading tokenization platform. Alex Cochand, Director of the SEI Venture Studio,
More news about: SEI Investments Company
Oct 02, 2025, 07:58 ET ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Oct 01, 2025, 08:45 ET Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Oct. 1, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Oct 01, 2025, 08:13 ET Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August
More news about: Berger Montague
Sep 30, 2025, 16:44 ET ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange
More news about: The Schall Law Firm
Sep 30, 2025, 09:01 ET Squarespace Refresh 2025: Built to Stand Out, Ready to Scale
for increasing visibility.SEO Scanner: A scanner that audits website content and suggests optimized titles, descriptions, and image alt text to boost traditional and AI-driven search rankings.AI Site Scanner: A scanner that will detect broken links and other website inefficiencies,
More news about: Squarespace, Inc.
Sep 30, 2025, 09:00 ET FDA dos EUA aprova Inluriyo (imlunestrant) para adultos com câncer de mama avançado ou metastático ER+, HER2- e com mutação ESR1
foram: diminuição da hemoglobina, dor musculoesquelética, diminuição do cálcio, diminuição dos neutrófilos, aumento de AST, fadiga, diarreia, aumento de ALT, aumento de triglicerídeos, náusea, diminuição de plaquetas, constipação, aumento de colesterol e dor abdominal. No estudo, 4,6% dos pacientes descontinuaram
More news about: Eli Lilly do Brasil
Sep 29, 2025, 14:56 ET ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Sept. 29, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline.
More news about: THE ROSEN LAW FIRM, P. A.
Sep 29, 2025, 08:45 ET Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
Sept. 29, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
More news about: The Gross Law Firm
Sep 29, 2025, 08:01 ET BenQ Launches GV32 LED Ceiling Projector for All-in-One, Grab-and-Go Home Entertainment
Versatility for Casual Gaming: The GV32 has a low input lag of 22.4ms (1080 @ 60Hz) with USB-C DP Alt Mode to support a great gaming experience, including with the Nintendo Switch. "The growing popularity
More news about: BenQ
Sep 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or
More news about: Pomerantz LLP
Sep 27, 2025, 12:48 ET STL vertieft Partnerschaft mit Netomnia zur Beschleunigung des zukunftsfähigen Glasfaserausbaus in Großbritannien
führendes Unternehmen für optische und digitale Lösungen, hat seine langjährige Partnerschaft mit Netomnia, dem zweitgrößten alternativen Netzbetreiber (Alt-Net) in Großbritannien, erweitert. Gemeinsam entwickeln die Unternehmen fortschrittliche optische Lösungen, die das kapitaleffiziente, zukunftsfähige Vollglasfasernetz
More news about: Sterlite Technologies Ltd - STL
Sep 26, 2025, 17:28 ET STL renforce son partenariat avec Netomnia, afin d'accélérer le déploiement de la fibre optique au Royaume-Uni.
domaine des solutions optiques et numériques, a étendu son partenariat de longue date avec Netomnia, le deuxième fournisseur de réseaux alternatifs (Alt-Net) du Royaume-Uni. Ensemble, les deux entreprises développent des solutions optiques avancées qui caractérisent le réseau à fibres optiques de Netomnia,
More news about: Sterlite Technologies Ltd - STL
Sep 26, 2025, 09:00 ET Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Sep 26, 2025, 02:30 ET STL deepens partnership with Netomnia to accelerate the UK's future-ready full-fibre rollout
optical and digital solutions company, has expanded its long-standing partnership with Netomnia, the UK's second-largest alternative network provider (Alt-Net). Together, the companies co-develop advanced optical solutions that underpin Netomnia's capitalefficient, future-ready full-fibre network across the
More news about: Sterlite Technologies Ltd - STL
Sep 26, 2025, 02:18 ET STL deepens partnership with Netomnia to accelerate the UK's future-ready full-fibre rollout
optical and digital solutions company, has expanded its long-standing partnership with Netomnia, the UK's second-largest alternative network provider (Alt-Net). Together, the companies co-develop advanced optical solutions that underpin Netomnia's capitalefficient, future-ready full-fibre network across the
More news about: Sterlite Technologies Ltd - STL
Sep 25, 2025, 17:21 ET ALTIMMUNE (NASDAQ: ALT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
Berger Montague PC is investigating claims under the federal securities laws against Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including
More news about: Berger Montague
Sep 25, 2025, 14:01 ET U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
laboratory abnormalities, were hemoglobin decreased, musculoskeletal pain, calcium decreased, neutrophils decreased, AST increased, fatigue, diarrhea, ALT increased, triglycerides increased, nausea, platelets decreased, constipation, cholesterol increased, and abdominal pain. In the study, 4.6% of patients
More news about: Eli Lilly and Company
Sep 25, 2025, 08:45 ET Investors in Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT
Sept. 25, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).
More news about: The Gross Law Firm
Sep 24, 2025, 16:18 ET INTERNATIONALE GESELLSCHAFT FÜR HAARWIEDERHERSTELLUNGSCHIRURGIE VERANSTALTET 33. WELTKONGRESS, 23. bis 25. OKTOBER 2025, IN BERLIN, DEUTSCHLAND, MIT AUSVERKAUFTEM LIVE-CHIRURGIE-WORKSHOP am 26
im Jahr 2024 jünger als die Allgemeinbevölkerung: 95 % der Patienten, die eine Haarwiederherstellung vornehmen lassen, sind zwischen 20 und 35 Jahre alt. Die dreitägige Konferenz und der ausverkaufte Live-Chirurgie-Workshop werden voraussichtlich mehr als 800 Ärzte und chirurgische Assistenten
More news about: International Society of Hair Restoration Surgery
Sep 24, 2025, 09:40 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities
More news about: Faruqi & Faruqi, LLP